Traditionally in the drug business there is a huge advantage to being first to market with an innovative new therapy. However this is not always the case. A fact which should not go unnoticed by the folks at Novo Nordisk. Novo has bet the farm on their recently submitted oral version of semaglutide, which when approved will be the first orally delivered GLP-1. We have little doubt the FDA will approve the drug, but we have lots of concern that this drug will reach the lofty sales estimates produced by the analysts who follow Novo.
Just as a . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.